Our present finding on the antiremodeling effects of mirabegron independently of β3-AR-eNOS mediated pathways could be interesting for physicians treating heart failure patients with reduced renal function since mirabegron could have anti-fibrotic effects in the early stages of uremic cardiomyopathy. Here, NOS3 is linked to heart failure.